Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 14,184 shares of the business's stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $51.62, for a total value of $732,178.08. Following the completion of the transaction, the chief executive officer directly owned 50,760 shares in the company, valued at approximately $2,620,231.20. This represents a 21.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Jack Bendheim also recently made the following trade(s):
- On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total value of $3,005,705.34.
- On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
- On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
- On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total transaction of $400,600.20.
- On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $268,322.37.
- On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total transaction of $271,692.64.
- On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.55, for a total transaction of $50,079.25.
- On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total transaction of $552,372.84.
- On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total transaction of $612,154.16.
- On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
Phibro Animal Health Stock Down 0.4%
NASDAQ PAHC opened at $51.52 on Thursday. The stock has a fifty day moving average of $40.75 and a 200-day moving average of $38.84. The stock has a market capitalization of $2.09 billion, a P/E ratio of 22.90, a price-to-earnings-growth ratio of 0.79 and a beta of 0.80. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $56.30. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.
Phibro Animal Health Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health's dividend payout ratio (DPR) is 21.33%.
Institutional Trading of Phibro Animal Health
A number of large investors have recently made changes to their positions in PAHC. Penserra Capital Management LLC acquired a new stake in Phibro Animal Health during the 3rd quarter worth $519,000. Capricorn Fund Managers Ltd acquired a new position in Phibro Animal Health in the third quarter valued at about $10,233,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health in the third quarter worth about $8,931,000. Bailard Inc. acquired a new stake in shares of Phibro Animal Health during the second quarter worth about $259,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Phibro Animal Health during the second quarter worth about $813,000. Institutional investors own 99.34% of the company's stock.
Wall Street Analyst Weigh In
PAHC has been the subject of a number of recent research reports. Weiss Ratings reissued a "buy (b-)" rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. Zacks Research downgraded Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Monday. Finally, JPMorgan Chase & Co. raised their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a research report on Friday, November 7th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $37.50.
Check Out Our Latest Report on PAHC
Phibro Animal Health Company Profile
(
Get Free Report)
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
